Lung Transplantation for COVID-19 Acute Respiratory Distress Syndrome: The British Columbian Experience With New Disease Pathology

Semin Thorac Cardiovasc Surg. 2024;36(4):445-449. doi: 10.1053/j.semtcvs.2022.12.004. Epub 2022 Dec 24.

Abstract

Lung transplantation is a life-saving treatment for patients with end-stage lung disease. COVID-19 has been associated with a severe and rapid decline in pulmonary function, in which case lung transplantation has been described to be effective. We herein describe 9 patients who underwent lung transplantation for COVID-19 acute respiratory distress syndrome, of whom 6 were bridged with extracorporeal membrane oxygenation (ECMO). The median time of pre-operative observation periods was 54 days to ensure no lung function recovery and the time to wean off extracorporeal membrane oxygenation was 3 days. Patients had comparable short-term survival outcomes to non-COVID-19 lung transplant recipients at our institution during the same time period. Lung transplantation for COVID-19-associated lung disease is feasible with comparable short-term outcomes and may liberate patients from extracorporeal supports.

Keywords: COVID; ECMO; Lung; Thoracic; Transplant.

MeSH terms

  • Adult
  • Aged
  • COVID-19* / complications
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Humans
  • Lung Transplantation*
  • Male
  • Middle Aged
  • Respiratory Distress Syndrome* / etiology
  • Respiratory Distress Syndrome* / surgery
  • Respiratory Distress Syndrome* / therapy
  • Respiratory Distress Syndrome* / virology
  • Retrospective Studies
  • SARS-CoV-2 / pathogenicity
  • Time Factors
  • Treatment Outcome